In The News 09/09/2026
Study defines Tumor-Associated Proximity Antigens (TAPAs), a new class of therapeutic targets identified by disease-associated spatial relationships rather than expression alone Industrialized high-resolution proximity mapping, “MetaMap” analysis, and graph learning uncover protein neighborhoods at scale, creating a systematic discovery engine for differentiated medicines Research provided the scientific foundation for IDP-001, InduPro’s lead bispecific antibody-drug conjugate […]
In The News 08/12/2026
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro’s proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), […]
In The News
05/27/2026
Experienced physician-scientist and life science executive, Dr. Redig will steer InduPro’s development strategy as the Company advances its lead program toward Phase 1 Studies SEATTLE, WA and CAMBRIDGE, MA— May 27, 2025 — InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, […]
In The News
04/07/2026
Just a month after striking a partnership with Sanofi on an autoimmune disease program, InduPro Therapeutics has landed a second pharma partnership focused on developing… More
In The News
01/07/2026
InduPro will leverage its proprietary platform to develop bi- and trispecific therapeutics that discover rationally selected Tumor Associated Proximity Antigens (TAPAs) to pair as co-targets with Tumor Associated Antigens, in collaboration with Lilly.
In The News
12/10/2025
SEATTLE, WA and CAMBRIDGE, MA— December 10, 2025 — InduPro, Inc., today announced a strategic equity investment and research collaboration with Sanofi. The agreement with Sanofi includes the right of first negotiation for InduPro’s bispecific PD-1 agonist program, which is currently in preclinical development for the treatment of autoimmune and inflammatory disorders.
